NK - NantKwest/ImmunityBio's COVID-19 vaccine candidate on go with early stage-study in South Africa

The South Africa Health Products Regulatory Authority has signed-off ImmunityBio's Phase 1 trial to evaluate its hAd5 T-cell vaccine, the company’s COVID-19 vaccine candidate.The same vaccine is currently being tested in a similar Phase 1 trial in the U.S., with no safety concerns identified to date.The vaccine candidate will be delivered subcutaneously and via a room-temperature oral capsule formulation. The company believes that the vaccine has the potential to serve as a universal T-cell boost to current vaccines or address mutations where other vaccines might fail, including the 501Y.V2 variant, which has been found in patients in South Africa.NantKwest ([[NK]] +5.3%) announced an agreement with ImmunityBio for the development, manufacture and commercialization of vaccines and therapeutics for COVID-19, in August last year.Then in December, NantKwest entered into a reverse merger agreement with ImmunityBio to create an immunotherapy and cell therapy company focused on oncology and infectious disease, under the ImmunityBio moniker.

For further details see:

NantKwest/ImmunityBio's COVID-19 vaccine candidate on go with early stage-study in South Africa